New York City-based Enzo Biochem has named Kevin Krenitsky, M.D., as the new president of its subsidiary, Enzo Clinical Labs. Krenitsky will replace Shahram Rabbani, who was formerly the treasurer, secretary, and director under his brother Elazar Rabbani, Ph.D., who is Enzo Biochem’s chairman and chief executive officer. Enzo Clinical Labs has exhibited significant growth over the past two years. Between 2007 and 2008, the subsidiary saw 79.5 percent revenue growth, according to Washington G-2’s recently released Laboratory Industry Strategic Outlook 2009.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

April 2009 - Table of Contents

LIR April 2009 (full PDF issue)

Economic Stimulus Bill’s $19 Billion in IT Investments Include Incentives for Pathologists, but Not Labs

California AG Alleges Billing Fraud in Suit Against Quest, LabCorp, and Five Other Labs

Survey Finds 63% of Labs Grappling With High Vacancy Rates; Medical Technologist Rate Highest at Over 10%

Genoptix Leads in FY2008 Productivity Benchmark Measures

Inside the Lab Industry: Stimulus Bill’s $19 Billion in IT Investment Provides Incentives, Penalties for Lab Industry

Cleveland Clinic Eyes $25 Million Reference Lab Expansion, Broadens Focus on Cardiac Esoteric Testing

Genoptix FY08 Revenues Up 96% to $116 Million; Growth Includes Move Into Solid Tumor Testing

Enzo Biochem Names New Clinical Lab President; Acquires Assay Designs

Lab Stocks Down 16% So Far in March; Down 7% So Far in 2009

LabCorp, Quest Name New Chief Medical Officers